FIBROGEN INC - COMMON

0.2639

13-June-25 13:45:00

15 minutes delayed

Stocks

-0.0446

-14.46%

Today's range

0.2423 - 0.2885

ISIN

N/A

Source

NASDAQ

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

05 Feb 2024 04:00:00 By Nasdaq GlobeNewswire
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

25 Jan 2024 04:00:00 By Nasdaq GlobeNewswire
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

09 Dec 2023 14:02:00 By Nasdaq GlobeNewswire
FibroGen Reports Third Quarter 2023 Financial Results

06 Nov 2023 13:01:00 By Nasdaq GlobeNewswire
FibroGen to Report Third Quarter 2023 Financial Results

23 Oct 2023 04:00:00 By Nasdaq GlobeNewswire
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

29 Aug 2023 13:15:00 By Nasdaq GlobeNewswire
FibroGen Reports Second Quarter 2023 Financial Results

07 Aug 2023 13:01:00 By Nasdaq GlobeNewswire
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

26 Jun 2023 04:04:00 By Nasdaq GlobeNewswire
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

07 Jun 2023 03:55:00 By Nasdaq GlobeNewswire
FibroGen to Present at Jefferies Global Healthcare Conference

06 Jun 2023 13:01:00 By Nasdaq GlobeNewswire
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

18 May 2023 04:30:00 By Nasdaq GlobeNewswire
FibroGen Reports First Quarter 2023 Financial Results

08 May 2023 13:01:00 By Nasdaq GlobeNewswire
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

08 May 2023 13:00:00 By Nasdaq GlobeNewswire
FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)

05 May 2023 04:30:00 By Nasdaq GlobeNewswire
FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value

01 May 2023 04:00:00 By Nasdaq GlobeNewswire
FibroGen to Report First Quarter 2023 Financial Results

24 Apr 2023 04:00:00 By Nasdaq GlobeNewswire
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

03 Apr 2023 04:00:00 By Nasdaq GlobeNewswire
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results

27 Feb 2023 13:01:00 By Nasdaq GlobeNewswire
FibroGen to Present at Cowen’s 43rd Annual Health Care Conference

27 Feb 2023 04:00:00 By Nasdaq GlobeNewswire
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results

17 Feb 2023 04:00:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.